Allopurinol and Quality of Life in Liver Cirrhosis

NCT05828836 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-10-31

No results posted yet for this study

Summary

The study aims to evaluate the impact of allopurinol on patients' related quality of life.

Conditions

  • Cirrhosis, Liver

Interventions

DRUG

Allopurinol Tablet

allopurinol300mg once daily

DRUG

Placebo

placebo once daily

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-01-15
Completion
2023-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05828836 on ClinicalTrials.gov